CD30 (Ki-1)-positive malignant lymphomas: Clinical, immunophenotypic, histologie, and genetic characteristics and differences with Hodgkin's disease Journal Article

Authors: Filippa, D. A.; Ladanyi, M.; Wollner, N.; Straus, D. J.; O'Brien, J. P.; Portlock, C.; Gangi, M.; Sun, M.
Article Title: CD30 (Ki-1)-positive malignant lymphomas: Clinical, immunophenotypic, histologie, and genetic characteristics and differences with Hodgkin's disease
Abstract: This study compares the histologie and immunophenotypic features of 71 cases of primary CD30+ diffuse large-cell lymphomas (DLCL) and 128 cases of Hodgkin's disease (HD) and discusses the clinical features of 52 patients with CD30+ DLCL. It includes analysis of sites of involvement, staging, response to treatment, sites and treatment of recurrences, and disease-free and overall survival. Diagnostic immunophenotypic differences were found between CD30+ DLCL and HD. All cases of CD30+ DLCL were positive for one or more common or lineage-specific lymphocyte antigens or for EMA. In contrast, 96.9% of HD cases were negative for CD45, CD45-RO, CD43, and CD20. The four exceptions are discussed. All cases of HD were negative for EMA. In patients with CD30+ DLCL, a T-cell phenotype was found in 60%, a null-cell type in 22%, and a B-cell type in 18% of the cases. The median age of patients with T- and null-cell phenotype was 22 years (range, 4 to 72). Fifty-two percent of them had high-stage (III and IV) disease and 61% had extranodal involvement at presentation, including 25% with skin lesions. Lymph nodes draining the skin lesions became involved in seven of 11 patients. No patient had initial bone marrow involvement. Most patients were treated with chemotherapy, and 83% had a complete remission. Fifty-four percent remain free of disease with a median follow-up of 47 months. Thirteen patients (29%) had one or more recurrences and five of them remain free of disease after salvage therapy, with a median follow-up period of 79 months. The clinical stage did not affect survival, probably as a result of different therapy. The t(2;5) translocation was found in five of 15 patients who had cytogenetic abnormalities. Of the other 10 cases, the translocation was detected by reverse transcriptase-polymerase chain reaction (RT-PCR) in four of five cases studied. All nine cases were of T- or null-cell phenotype. The cases of B-cell CD30+ OLCL had a characteristic immunophenotype. All were negative for EMA. These patients were older and had frequent bone marrow involvement but no skin infiltration by lymphoma. All three patients who were human immunodeficiency virus-positive (HIV+) had lymphomas of B-cell lineage. Detection of the t(2;5) translocation by molecular genetics is a useful and highly specific marker in the differential diagnosis between HD and CD30+ DLCL. © 1996 by The American Society of Hematology.
Keywords: adolescent; adult; cancer survival; child; controlled study; aged; aged, 80 and over; child, preschool; middle aged; survival analysis; major clinical study; clinical feature; histopathology; cancer localization; cancer recurrence; cancer combination chemotherapy; cancer radiotherapy; cancer staging; antineoplastic agent; t lymphocyte; cytogenetics; hodgkin disease; b lymphocyte; cancer regression; lymphoma; immunophenotyping; large cell lymphoma; bone marrow transplantation; cd30 antigen; lymphocyte antigen; chromosome translocation 2; humans; human; male; female; priority journal; article
Journal Title: Blood
Volume: 87
Issue: 7
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 1996-04-01
Start Page: 2905
End Page: 2917
Language: English
PUBMED: 8639911
PROVIDER: scopus
Notes: Article -- Export Date: 22 November 2017 -- Source: Scopus